Peptides DB
Research-centric peptide and protocol reference hub
Study 2 of 2Orforglipron (LY-3502970) literatureLancet (London, England) · Phase 3Top journal2026

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

Not reported in abstract.

Read at Lancet (London, England)Add to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
1
Preclinical · this one
0
Observational
0
Open-label
0
Randomised
1
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 32026

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Orforglipron (LY-3502970) corpus

AComparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.europepmc · 2026 · -3.52 kg/m² BMI reduction at 45 mg vs placebo.Human